Paxlovid

2022 - 12 - 13

Post cover
Image courtesy of "The New York Times"

Paxlovid Rebound: What to Watch For and Should You be Worried (The New York Times)

Some people who had taken the antiviral medication experienced a recurrence of Covid symptoms after their infection appeared to have cleared up.

Those who do experience a recurrence of symptoms typically do so within a few days or a week, said Dr. [study published](https://www.medrxiv.org/content/10.1101/2022.06.21.22276724v1) in June found that of 13,644 adult coronavirus patients who took Paxlovid or another treatment, Molnupiravir, about 5 percent tested positive again within 30 days and 6 percent experienced symptoms again. But that rebound effect isnโ€™t limited to people who have taken Paxlovid: a

Post cover
Image courtesy of "Reuters"

U.S. to pay Pfizer nearly $2 bln for more Paxlovid courses in 2023 (Reuters)

The U.S. government agreed to pay drugmaker Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral drug Paxlovid, ...

diplomatic communications with China remain open after the shooting down of a Chinese spy balloon this month, but contact between the countries' militaries "unfortunately" remains shut down, the White House said on Friday. (This includes the Reuters Weekend Briefing.) All the news you need to start your day.

Explore the last week